Senseonics Holdings

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics’ mission is to provide reliable and accurate data for people living with diabetes, enabling them to live a normal life and gain control of their diabetes.

Our vision is a world where diabetes no longer limits or disrupts your life, where people with diabetes can lead normal and confident lives, free from the daily burden of diabetes.

Senseonics has been recognized for its commitment and success in creating innovative and reliable products, including being named as one of the 2020 Edison Award finalists for its cutting-edge continuous glucose monitoring technology and products.